Berberine: A Comprehensive Reference
1. Identity, Chemistry, and Natural Sources
Berberine (systematic name: 5,6-dihydro-9,10-dimethoxybenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium) is a nonbasic, quaternary benzylisoquinoline alkaloid and one of the most studied phytochemicals in natural products pharmacology. It is a natural quaternary amine isoquinoline alkaloid with a characteristic yellow color and a very bitter taste. Its chemical structure features three aromatic rings and a quaternary nitrogen, which enables it to interact with numerous biological targets.
Berberine has been detected, isolated, and quantified from various plant families and genera including Annonaceae, Berberidaceae (including Berberis, Caulophyllum, Mahonia, and Nandina), Menispermaceae (Tinospora), Papaveraceae (Argemone, Chelidonium, Corydalis, and Sanguinaria), Ranunculaceae (Coptis, Hydrastis, and Xanthorhiza), and Rutaceae (Evodia, Phellodendron, and Zanthoxyllum).
The genus Berberis is well-known as the most widely distributed natural source of berberine. The bark of B. vulgaris contains more than 8% alkaloids, berberine being the major alkaloid at about 5%. Berberine is mainly extracted from the roots and rhizomes of Berberis vulgaris (barberry), Berberis aristata (tree turmeric), Berberis aquifolium (Oregon grape), Hydrastis canadensis (goldenseal), Xanthorhiza simplicissima (yellow root), Phellodendron amurense (Amur cork tree), Coptis chinensis (Chinese goldthread), Tinospora cordifolia, and Argemone mexicana (prickly poppy), for the production of various nutraceutical formulations.
Berberine occurs as an active constituent in the root, stem bark, and rhizome of many medicinal plants. The analysis of several plant species from the family Berberidaceae and Ranunculaceae has shown that berberine is mostly concentrated in the roots and leaves, while fruits contain only nominal amounts of this alkaloid.
Common Forms and Preparations
A majority of commercial products contain berberine chloride or berberine sulfate. Several derivatives have been produced through chemical modification of berberine. The chemical compound salt forms include hydrochloride, sulfate, and phosphate, which vary in water solubility; hydrochloride salt is less soluble in water, whereas sulfate and phosphate salts are relatively more water-soluble.
Regulatory status varies by jurisdiction: in Canada, berberine is classified as a natural health product (NHP) and is permitted for sale without major restrictions. In the United States, it is marketed as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA), where manufacturers are responsible for ensuring safety. European regulations are more fragmented.
2. Traditional and Historical Use
In Asia, the extensive use of the stem, stem bark, roots, and root bark of plants rich in berberine, particularly Berberis species, has more than 3,000 years of history. They have been used as raw material or as an important ingredient in Ayurvedic and traditional Chinese medicine.
Berberine has a 3,000-year history of use in Ayurvedic, Persian, and Chinese traditional medicine, particularly for its antidiarrheal and antitrachoma activity.
Ayurvedic Medicine
In Ayurveda, Berberis species have been traditionally used for the treatment of a wide range of infections of the ear, eye, and mouth, for quick healing of wounds, curing hemorrhoids, indigestion and dysentery, or treatment of uterine and vaginal disorders. It has also been used to reduce obesity, and as an antidote for the treatment of scorpion sting or snakebite.
Plants containing berberine have been used medicinally for thousands of years in Ayurvedic medicine and traditional Chinese medicine. In Ayurvedic medicine, plants rich in berberine have been used for treating infections, for promoting wound healing, and as a remedy for gastrointestinal disorders. Traditionally, berberine has also been used as a treatment against various bacteria, fungi, and viruses.
Traditional Chinese Medicine (TCM)
Coptidis rhizoma (rhizomes of Coptis chinensis), a plant containing berberine, is a famous herb very frequently used in traditional Chinese medicine for the elimination of toxins, "damp-heat syndromes," "purge fire," and to "clear heat." Berberine is commonly used in TCM, Ayurveda, and other medicinal traditions to treat infections, diarrhea, and inflammatory disorders. In China, it is frequently used for the adjuvant treatment of type 2 diabetes, hyperlipidemia, and hypertension.
Berberine extracts and decoctions are traditionally used for their activities against a variety of microorganisms including bacteria, viruses, fungi, protozoa, and helminthes, in Ayurvedic, Chinese, and Middle-Eastern folk medicines.
Other Traditional Systems
Within the Berberidaceae family, Mahonia aquifolium has been traditionally used for various skin conditions. Native American traditional healers utilized plants like Oregon grape and goldenseal, which are berberine-containing species, for antiseptic and anti-inflammatory purposes.
3. Key Constituents and Active Compounds
Berberine itself is the principal bioactive alkaloid in berberine-containing plants. It is known as a very important natural alkaloid and serves as a scaffold for the synthesis of several bioactive derivatives by means of condensation, modification, and substitution of functional groups, enabling the design of new, selective, and powerful drugs.
Berberine, as an isoquinoline alkaloid naturally derived from Berberis species, has broad-spectrum pharmacological activities and significant potency for the treatment of metabolic, cardiovascular, neurological, and inflammatory diseases by modulation of cellular signaling pathways, antimicrobial action, and cytoprotection.
4. Mechanisms of Action
AMPK Activation
AMP-activated protein kinase (AMPK) is a cellular energy sensor that, upon activation, stimulates catabolic processes such as fatty acid oxidation, glucose uptake, and lipolysis, while inhibiting anabolic processes such as gluconeogenesis, fatty acid synthesis, and cholesterol synthesis. Studies in HepG2 human hepatoma cells found that berberine inhibits cholesterol and triglyceride synthesis in a manner similar to the AMPK activator AICAR. Significant increases in AMPK phosphorylation and AMPK activity were observed when cells were incubated with berberine. Activation of AMPK was further demonstrated by measuring phosphorylation of acetyl-CoA carboxylase, a substrate of AMPK, correlated with a subsequent increase in fatty acid oxidation.
LDL Receptor Upregulation and PCSK9 Inhibition
Berberine significantly increases hepatic low-density lipoprotein receptor (LDLR) expression and reduces the expression and secretion of the LDLR modulator proprotein convertase subtilisin/kexin type 9 (PCSK9). Berberine upregulates LDLR expression through the activation of the signaling cascade AMPK/Raf-1/MEK/ERK, although the JNK pathway plays a role as well. These findings indicate that berberine, in addition to upregulating the LDLR, inhibits lipid synthesis in human hepatocytes through activation of AMPK. These effects may account for the strong reduction of plasma triglycerides observed in clinical trials.
Glucose Metabolism
The antidiabetic actions of berberine include increasing secretion of insulin, improving insulin resistance, and ameliorating dyslipidemia. The hypoglycemic effect of berberine is also partially mediated by an anti-inflammatory mechanism, which adds evidence indicating that type 2 diabetes mellitus is a low-grade inflammatory disease. A randomized, double-blind, placebo-controlled, two-period crossover, single-dose, phase 1 clinical trial (NCT03972215) demonstrated that berberine enhances glucose-stimulated insulin secretion in humans without altering basal insulin levels.
Anti-Atherosclerotic Effects
Berberine has been shown to exert atheroprotective effects through reducing plasma cholesterol, particularly LDL cholesterol, via LDL receptor-dependent and LDL receptor-independent mechanisms, inhibiting migration and inflammatory activity of macrophages, improving functionality of endothelial cells via antioxidant activities, and suppressing proliferation of vascular smooth muscle cells.
Among the signaling pathways through which berberine regulates intracellular processes, AMP-activated protein kinase (AMPK) plays a central and critical role.
Gut Microbiota Modulation
Berberine has attracted growing attention due to its pleiotropic immunomodulatory, neuroprotective, and gut-homeostasis-modulating properties, which involve reshaping the gut microbiota and underscore its therapeutic relevance within the gut–microbiome–brain axis. Preclinical findings suggest that prevention of obesity and insulin resistance by berberine in high-fat diet-fed animals is at least partially mediated by structural modulation of the gut microbiota, which may help to alleviate inflammation by reducing the exogenous antigen load in the host and elevating short-chain fatty acid (SCFA) levels in the intestine.
Antimicrobial Activity
As a pleiotropic antimicrobial agent, berberine disrupts microbial proliferation through dual inhibition of bacterial protein biosynthesis and nucleic acid replication, effectively suppressing pathogenic colonization in Streptococcus haemolyticus, Staphylococcus aureus, Neisseria gonorrhoeae, and Shigella species while enhancing leukocyte phagocytic activity.
5. Scientific Evidence by Area of Use
5.1 Type 2 Diabetes and Glycemic Control
This is the area with the most substantial clinical evidence for berberine, supported by multiple systematic reviews and meta-analyses of randomized controlled trials (RCTs).
Meta-analysis (2022, Frontiers in Pharmacology): A meta-analysis searched eight databases for RCTs with berberine as intervention in patients with type 2 diabetes, published up until November 2021. Thirty-seven studies involving 3,048 patients were included. Results showed that berberine could significantly reduce fasting plasma glucose (WMD = −0.82 mmol/L, 95% CI −0.95 to −0.70), HbA1c (WMD = −0.63%, 95% CI −0.72 to −0.53), and 2-hour postprandial blood glucose (WMD = −1.16 mmol/L, 95% CI −1.36 to −0.96).
Meta-analysis (2024, Frontiers in Pharmacology): A more recent meta-analysis including 50 studies involving 4,150 participants found that berberine alone significantly reduced fasting plasma glucose (FPG) (MD = −0.59 mmol/L, p = 0.048), 2-hour postprandial blood glucose (MD = −1.57 mmol/L, p < 0.01), LDL-C (MD = −0.30 mmol/L, p < 0.01), total cholesterol (MD = −0.30 mmol/L, p = 0.034), and triglycerides (MD = −0.35 mmol/L, p < 0.01).
Meta-analysis (2021, multiple RCTs): Forty-six trials were assessed. Analysis of berberine applied alone or with standard diabetic therapies versus the control group revealed significant reductions in HbA1c (MD = −0.73; 95% CI −0.97 to −0.51), FPG (MD = −0.86; 95% CI −1.10 to −0.62), and 2-hour postprandial glucose (MD = −1.26; 95% CI −1.64 to −0.89). Improved insulin resistance was assessed by lowering fasting insulin (MD = −2.05), HOMA-IR (MD = −0.71), and BMI (MD = −1.07).
Evidence strength and limitations: The evidence of berberine for treating type 2 diabetes should be carefully interpreted due to the low methodological quality, small sample size, limited number of trials, and unidentified risks of bias in individual studies. Included studies were mostly conducted in China, lacking adequate global data, which weakens the extrapolation of results. The overall evidence base is positive in direction but methodologically heterogeneous and geographically concentrated.
5.2 Dyslipidemia and Lipid Metabolism
A comprehensive systematic review and meta-analysis of 27 RCTs found that berberine effectively reduced LDL cholesterol (−0.65 mmol/L, 95% CI −0.75 to −0.56), triglycerides (−0.39 mmol/L, 95% CI −0.59 to −0.19), and total cholesterol (−0.66 mmol/L, 95% CI −1.02 to −0.31) and increased HDL cholesterol (+0.07 mmol/L, 95% CI 0.04 to 0.1). No serious adverse events were reported in these trials.
Umbrella meta-analysis (2023): An umbrella meta-analysis described as the most comprehensive quantitative review of meta-analyses on the subject identified 13 meta-analyses of RCTs with 17,256 participants, which had high quality based on the AMSTAR checklist. Results showed that berberine significantly decreased waist circumference, LDL-C, total cholesterol, triglycerides, and improved HDL-C levels, confirming the beneficial effect of berberine on lipid profile.
Cardiovascular risk factor meta-analysis (2022, Frontiers in Nutrition): Pooled results from RCTs showed berberine significantly reduced triglycerides (WMD = −23.70 mg/dL), total cholesterol (WMD = −20.64 mg/dL), LDL-C (WMD = −9.63 mg/dL), fasting blood glucose (WMD = −7.74 mg/dL), insulin (WMD = −3.27 mIU/mL), HbA1c (WMD = −0.45%), HOMA-IR (WMD = −1.04), systolic blood pressure (WMD = −5.46 mmHg), and body weight (WMD = −0.84 kg), while increasing HDL cholesterol (WMD = +1.37 mg/dL).
Evidence strength: Systematic reviews and meta-analyses of clinical trials have shown a lipid-lowering effect of berberine in people with hyperlipidemia with or without coronary heart disease or diabetes, as well as potential benefits on blood pressure and adiposity, with no serious adverse events. However, these trials vary in quality and design, making meta-analyses difficult to interpret. Publication bias is also possible. The lipid-lowering evidence is among the most consistent for berberine and has been recognized by institutional sources including the NCCIH.
5.3 Non-Alcoholic Fatty Liver Disease (NAFLD)
RCT (multi-center, 184 patients): A randomized, parallel-controlled, open-label clinical trial conducted in three medical centers enrolled 184 eligible patients with NAFLD who received lifestyle intervention (LSI), LSI plus pioglitazone 15 mg daily, or LSI plus berberine 0.5 g three times daily for 16 weeks. Compared with LSI alone, berberine treatment plus LSI resulted in a significant reduction of hepatic fat content (52.7% vs. 36.4%, p = 0.008), with better improvement in body weight, HOMA-IR, and serum lipid profiles. Berberine was more effective than pioglitazone 15 mg daily in reducing body weight and improving lipid profile.
Meta-analysis (2024, Journal of Translational Medicine): Among 10 RCTs involving 811 patients, berberine demonstrated significant reductions in ALT (SMD = −0.72), AST (SMD = −0.79), GGT (SMD = −0.62), triglycerides (SMD = −0.59), total cholesterol (SMD = −0.74), LDL-C (SMD = −0.53), HOMA-IR (SMD = −1.56), and BMI (SMD = −0.58). Berberine exhibited a favorable safety profile, with only mild gastrointestinal adverse events reported.
Berberine exhibits potential for treating NAFLD, but clinical evidence remains inconclusive. The number of high-quality, large-scale RCTs is still limited.
5.4 Obesity and Body Weight
Berberine has been shown to decrease body weight, body mass index, and waist circumference in obese patients with type 2 diabetes. Meta-analyses of RCTs documented a significant reduction in body weight (WMD = −0.84 kg), BMI, and waist circumference with berberine supplementation.
Preclinically, berberine's multimodal anti-obesity mechanisms include AMPK activation enhancing lipolysis and β-oxidation, and peroxisome proliferator-activated receptor modulation. Human clinical evidence for meaningful standalone weight loss, however, remains preliminary, with effect sizes small in absolute terms and most studies evaluating berberine as an adjunct rather than a primary weight-loss intervention.
5.5 Gut Microbiota and Gastrointestinal Health
The berberine-related restoration of a favorable ratio of beneficial microbial bacteria in the gut leads to a reduction in bacterial colonization-related inflammation. Through this mechanism, a number of beneficial effects of the alkaloid in various internal diseases have been demonstrated, including NAFLD.
Berberine has attracted growing attention due to its pleiotropic immunomodulatory, neuroprotective, and gut-homeostasis-modulating properties, which involve reshaping the gut microbiota and underscore its therapeutic relevance within the gut–microbiome–brain axis. Current scientific evidence regarding the anti-inflammatory mechanisms of berberine in inflammatory bowel disease (IBD) is under active investigation. However, formal clinical evidence from large RCTs in IBD remains limited and predominantly preclinical.
In patients with NAFLD, berberine has been shown clinically to improve hepatic fat content, apolipoprotein B (ApoB), alanine aminotransferase (ALT), and aspartate aminotransferase (AST).
5.6 Cardiovascular Effects
Berberine has demonstrated beneficial effects in hypercholesterolemic subjects and diabetic patients. Evidence suggests that berberine may have additional beneficial effects on high blood pressure when used in combination with the medication amlodipine.
Evidence for direct reduction of cardiovascular events (such as myocardial infarction or stroke) in humans is not yet established; published RCTs have focused on surrogate markers (lipid panels, blood pressure, glucose) rather than hard cardiovascular outcomes.
5.7 Antimicrobial Use
Berberine is used for its purported antioxidant and antimicrobial properties for a host of conditions, including H. pylori infection. Preclinical studies suggest antimicrobial, anti-inflammatory, antioxidant, and atheroprotective properties, as well as potential antitumor effects. Clinical evidence for antimicrobial applications in humans is substantially less developed than the metabolic evidence, and most antimicrobial data derives from in vitro studies.
6. Pharmacokinetics and Bioavailability
The therapeutic use of berberine is still marred by poor oral bioavailability. The bioavailability of berberine is extremely low. Only approximately 0.5% of orally ingested berberine is absorbed in the small intestine, and approximately 0.36% can enter the systemic circulation. About 56% of ingested berberine is not absorbed, and an additional 43.5% is lost due to metabolism in the small intestine.
After oral ingestion, berberine undergoes extensive first-pass metabolism in the liver and intestines. Its oral bioavailability is remarkably low, estimated at less than 5%, which means the gastrointestinal tract is exposed to the brunt of the compound before it reaches systemic circulation.
Despite this paradox of poor systemic bioavailability but documented clinical activity, researchers have proposed several explanations, including high gastrointestinal concentrations producing local effects on gut microbiota, and the activity of berberine's metabolites. While both short- and long-term uses of berberine are generally regarded as safe, with only a few side effects reported — primarily digestive issues such as bloating, nausea, diarrhea, or constipation — regulatory oversight varies widely across countries.
Several formulation strategies have been investigated to improve bioavailability, including micellar formulations, cyclodextrin complexation, and co-administration of absorption enhancers such as vitamin E TPGS.
7. Dosage Forms and Reported Dosages
Berberine is commercially available in oral capsule and tablet forms. The following dosages represent those reported in clinical studies and reviews, not prescriptive recommendations:
- Oral administration of berberine at 1.0 g per day for 3 months has been used in human trials examining effects on type 2 diabetes and dyslipidemia. Berberine hydrochloride is the most common form.
- In the NAFLD multi-center RCT, berberine was administered at 0.5 g three times daily (1.5 g/day) for 16 weeks alongside lifestyle intervention.
- In the 37-trial meta-analysis covering 3,048 patients with type 2 diabetes, berberine produced significant reductions in glycemic markers across varying dose regimens included in constituent trials.
- In a 30-day crossover human study, participants received 1,000 mg of berberine daily (as two capsules of a micellar formulation) to examine safety markers related to liver and kidney function.
The most commonly reported dose in clinical trials is 500 mg administered two to three times per day (1,000–1,500 mg/day). However, reported durations in most trials are short — typically 8 to 16 weeks — and it is not clear regarding the safety of long-term berberine intake for the chronicity of conditions such as diabetes.
8. Body Systems and Health Areas Associated with Berberine
- Metabolic / Endocrine: Blood glucose regulation, insulin sensitivity, type 2 diabetes management, obesity, metabolic syndrome
- Cardiovascular: Lipid-lowering (LDL-C, TC, TG reduction; HDL-C increase), blood pressure, atherosclerosis-related markers
- Hepatic: Non-alcoholic fatty liver disease; liver enzyme normalization (ALT, AST, GGT)
- Gastrointestinal: Diarrhea, gut microbiota modulation, inflammatory bowel disease (preclinical and early clinical)
- Immunological / Inflammatory: General anti-inflammatory effects, cytokine modulation
- Antimicrobial: Activity against bacteria, fungi, protozoa, and viruses (largely in vitro and historical)
- Dermatological: Skin infections and conditions (historical; limited modern clinical data)
9. Safety, Adverse Effects, and Drug Interactions
General Safety Profile
In general, when taken orally, berberine is well tolerated; however, it is not without its risks and side effects. The most common adverse effects include abdominal pain, constipation, diarrhea, nausea, and vomiting.
Berberine has not been linked to serum aminotransferase elevations during therapy nor to instances of clinically apparent liver injury. In a 30-day crossover study, compared to placebo, no statistically significant changes in any safety markers related to liver or kidney health were detected.
Pregnancy and Neonatal Contraindications
People who are pregnant or breastfeeding should not use berberine, and it should not be given to infants. Berberine can cause or worsen jaundice in newborn infants and could lead to a life-threatening problem called kernicterus.
Drug Interactions via CYP450 Inhibition
Berberine inhibits CYP3A4, CYP2D6, and CYP2C9 — cytochrome P450 enzymes that metabolize statins, blood thinners, immunosuppressants, antidepressants, and many other drugs. This creates genuine drug interaction risk: combining berberine with simvastatin, warfarin, or cyclosporine can raise those drugs' blood levels to potentially toxic ranges.
Cyclosporine/Tacrolimus: The cyclosporine interaction is particularly well-documented. A study in the European Journal of Clinical Pharmacology showed that berberine increased cyclosporine blood levels by 88% in transplant patients, requiring immediate dose reduction to prevent kidney toxicity. This illustrates the magnitude of berberine's enzyme-inhibiting potential.
Warfarin: Case reports and cohort analyses document changes in INR when berberine is started or stopped in patients taking warfarin. Berberine can alter anticoagulation control and increase bleeding or clotting risk.
Antidiabetic medications: When taken with prescription diabetes medications (e.g., insulin, metformin, sulfonylureas), there is a risk of additive effects, potentially leading to hypoglycemia. Symptoms of hypoglycemia include dizziness, sweating, confusion, and rapid heart rate.
Metformin combination: Many people take berberine and metformin together and often experience additional glucose lowering and increased gastrointestinal side effects such as diarrhea. This combination can be safe when monitored.
P-Glycoprotein Interaction
P-glycoprotein (P-gp) is a major drug efflux pump found in the gut, liver, kidneys, and blood-brain barrier. It acts as a cellular transporter, pushing drugs and toxins out of cells. Berberine has been noted to interact with this transporter, which may affect the absorption and distribution of co-administered medications.
Regulatory and Quality Concerns
A study funded by the National Center for Complementary and Integrative Health (NCCIH) found that some commercial goldenseal dietary supplements (a major berberine source) did not contain much goldenseal and instead included ingredients not listed on their labels. This highlights the importance of product quality and standardization in the supplement market.
10. Overall Evidence Assessment
There is some evidence that berberine may have a modest effect on lowering blood glucose levels in people with type 2 diabetes and may reduce cholesterol levels. The most robust signal lies in glycemic control and lipid modulation, supported by multiple meta-analyses of RCTs. However, several structural limitations apply across the evidence base:
- Included studies are mostly conducted in China, lacking adequate global data, which weakens the extrapolation of results.
- Evidence should be interpreted carefully due to low methodological quality, small sample sizes, and limited numbers of trials in many areas.
- Clinical research investigating the use of berberine in humans is limited. Although numerous clinical trials have been conducted or are underway, as of 2025, berberine has frequently been withdrawn as a drug candidate and is not approved as a prescription drug in any country.
- The therapeutic use of berberine is still hampered by poor oral bioavailability.
References
- Neag MA et al. "Berberine: Botanical Occurrence, Traditional Uses, Extraction Methods, and Relevance in Cardiovascular, Metabolic, Hepatic, and Renal Disorders." Frontiers in Pharmacology, 2018. PMC6111450
- LiverTox: "Berberine." NIH National Library of Medicine / NCBI Bookshelf
- National Center for Complementary and Integrative Health (NCCIH): "In the News: Berberine." NIH
- NCCIH: "Herb-Drug Interactions: What the Science Says." NIH
- Nutrition Reviews: "Berberine: A Bitter Phytochemical With Diversely Sweet Therapeutic Properties." Oxford Academic, 2025
- Xu et al. "Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis." Frontiers in Pharmacology, 2022. PMC9709280
- "The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." PMC8696197
- PubMed: "Effects of administering berberine alone or in combination on type 2 diabetes mellitus: a systematic review and meta-analysis." PMID 39640489
- "Berberine in the Treatment of Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis." PMC3478874
- Zamani M et al. "The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis." Frontiers in Nutrition, 2022
- "Promising Anti-atherosclerotic Effect of Berberine: Evidence from In Vitro, In Vivo, and Clinical Studies." PubMed, 2020. PMID 32789786
- Brusq JM et al. "Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine." Journal of Lipid Research, 2006
- "Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies." Atherosclerosis, 2015
- "The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review." Journal of Translational Medicine, 2024. PMC10908013
- "Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease." PMC4529214
- "Berberine as a multi-target therapeutic agent for obesity: from pharmacological mechanisms to clinical evidence." European Journal of Medical Research / PMC, 2025. PMC12160363
- "The mechanism of berberine alleviating metabolic disorder based on gut microbiome." Frontiers in Cellular and Infection Microbiology, 2022. PMC9452888
- "Berberine in Bowel Health: Anti-Inflammatory and Gut Microbiota Modulatory Effects." MDPI / PMC, 2025. PMC12732474
- "Structural Changes of Gut Microbiota during Berberine-Mediated Prevention of Obesity and Insulin Resistance in High-Fat Diet-Fed Rats." PMC3411811
- "A 30-Day Randomized Crossover Human Study on the Safety and Tolerability of a New Micellar Berberine Formulation with Improved Bioavailability." PMC12028944
- Memorial Sloan Kettering Cancer Center: "Berberine." Integrative Medicine herb monograph
- Mohapatra N et al. "A comprehensive compendium of berberine: sources, chemistry, and pharmacological activities." Journal of the Science of Food and Agriculture, 2026
- "Pharmacokinetics of berberine, the main constituent of Berberis vulgaris L.: A comprehensive review." Phytotherapy Research
- "Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial." PMC8401658
- "Efficacy and underlying mechanisms of berberine against lipid metabolic diseases: a review." Frontiers in Pharmacology, 2023
- "Berberine: A Rising Star in the Management of Type 2 Diabetes—Novel Insights into Its Anti-Inflammatory, Metabolic, and Epigenetic Mechanisms." Pharmaceuticals, 2025
Go back